Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Eur J Endocrinol ; 185(4): G35-G42, 2021 Aug 27.
Article in English | MEDLINE | ID: covidwho-1448609


COVID-19 has changed the nature of medical consultations, emphasizing virtual patient counselling, with relevance for patients with diabetes insipidus (DI) or hyponatraemia. The main complication of desmopressin treatment in DI is dilutional hyponatraemia. Since plasma sodium monitoring is not always possible in times of COVID-19, we recommend to delay the desmopressin dose once a week until aquaresis occurs allowing excess retained water to be excreted. Patients should measure their body weight daily. Patients with DI admitted to the hospital with COVID-19 have a high risk for mortality due to volume depletion. Specialists must supervise fluid replacement and dosing of desmopressin. Patients after pituitary surgery should drink to thirst and measure their body weight daily to early recognize the development of postoperative SIAD. They should know hyponatraemia symptoms. Hyponatraemia in COVID-19 is common with a prevalence of 20-30% and is mostly due to SIAD or hypovolaemia. It mirrors disease severity and is an early predictor of mortality. Hypernatraemia may also develop in COVID-19 patients, with a prevalence of 3-5%, especially in ICU, and derives from different multifactorial reasons, for example, due to insensible water losses from pyrexia, increased respiration rate and use of diuretics. Hypernatraemic dehydration may contribute to the high risk of acute kidney injury in COVID-19. IV fluid replacement should be administered with caution in severe cases of COVID-19 because of the risk of pulmonary oedema.

COVID-19/epidemiology , Diabetes Insipidus/therapy , Endocrinology/standards , Hyponatremia/therapy , Ambulatory Care/methods , Ambulatory Care/standards , Consensus , Diabetes Insipidus/epidemiology , Diabetes Insipidus/pathology , Distance Counseling/methods , Distance Counseling/standards , Endocrinology/history , Endocrinology/trends , Expert Testimony , History, 21st Century , Hospitalization/statistics & numerical data , Humans , Hyponatremia/epidemiology , Hyponatremia/pathology , Pandemics , Practice Patterns, Physicians'/history , Practice Patterns, Physicians'/standards , Practice Patterns, Physicians'/trends , SARS-CoV-2 , Severity of Illness Index , Telemedicine/history , Telemedicine/methods , Telemedicine/standards
J Neurovirol ; 26(5): 797-799, 2020 10.
Article in English | MEDLINE | ID: covidwho-1070964


There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.

Betacoronavirus/pathogenicity , Coronavirus Infections/complications , Guillain-Barre Syndrome/complications , Hyponatremia/complications , Pneumonia, Viral/complications , Acute Disease , Aged , Anticoagulants/therapeutic use , COVID-19 , Coronavirus Infections/pathology , Coronavirus Infections/therapy , Coronavirus Infections/virology , Disease Progression , Enoxaparin/therapeutic use , Female , Guillain-Barre Syndrome/pathology , Guillain-Barre Syndrome/therapy , Guillain-Barre Syndrome/virology , Humans , Hyponatremia/pathology , Hyponatremia/therapy , Hyponatremia/virology , New York City , Pandemics , Plasmapheresis , Pneumonia, Viral/pathology , Pneumonia, Viral/therapy , Pneumonia, Viral/virology , SARS-CoV-2